Further studies showed that the expression of IFN receptor type 2 (IFNAR2) in HCC tissue samples correlates significantly with clinical response to IFN-α/5-FU combination therapy (Ota et al, 2005; Nagano et al, 2007a). Here, IFNAR2 is linked to hepatocellular carcinoma.